On October 23, 2015, the CHMP has recommended the suspension of Inductos, an implant used to help new bone develop in patients with spinal disc problems and leg fractures. EMA started a review of Inductos following an inspection by Dutch and Spanish authorities, which found the production site of the absorbable sponge to be noncompliant with manufacturing requirements. Specifically, the inspectors noted that the manufacturer, located in the United States, did not have adequate measures in place to prevent particle contamination of the sponges. Hence, the CHMP concluded that Inductos should be suspended until the manufacturing issues are satisfactorily addressed.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.